Medline and Predictive Oncology Compared: Which is the Better Business?

A head-to-head review of the two manufacturing companies reveals Medline's advantages.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Predictive Oncology (NASDAQ:AGPU) and Medline (NASDAQ:MDLN) are both manufacturing companies, but a comparison of the two businesses shows Medline has the edge. Medline has lower revenue but higher earnings than Predictive Oncology, and stronger institutional ownership and more favorable analyst ratings suggest Medline is the preferred stock.

Why it matters

This analysis provides insight into the relative strengths and weaknesses of these two manufacturing companies, which could help investors make more informed decisions about which stock to invest in.

The details

The comparison looks at key metrics like net margins, return on equity, return on assets, revenue, earnings per share, and valuation. It also examines factors like institutional ownership, insider ownership, and analyst recommendations. Medline comes out ahead on 6 out of the 9 factors compared.

  • Medline was founded in 1966.
  • Predictive Oncology Inc. was formerly known as Precision Therapeutics Inc. and changed its name in June 2019.

The players

Medline

A medical supply company that is the largest provider of medical-surgical products and supply chain solutions serving all points of care, based on total net sales of med-surg products.

Predictive Oncology Inc.

A knowledge-driven company that focuses on developing personalized cancer therapies using artificial intelligence, operating in four segments: Helomics, zPREDICTA, Soluble, and Skyline.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights Medline's advantages over Predictive Oncology in terms of profitability, valuation, and analyst sentiment, making it the more favorable stock between the two manufacturing companies.